Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$18.07

0.17 (0.95%)

07:15
10/03/16
10/03
07:15
10/03/16
07:15

Lexicon presents data from TELECAST Phase 3 study at NANETS

Lexicon Pharmaceuticals announced that data from its TELECAST Phase 3 study were presented at the 2016 Annual Symposium of the North American Neuroendocrine Tumor Society, held September 30 to October 1 in Jackson, Wyoming, by Dr. Marianne Pavel in a presentation, entitled "Efficacy and Safety Results of Telotristat Ethyl in Patients with Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial." Safety and tolerability was one of the primary objectives of the TELECAST study, and telotristat ethyl was well tolerated during the double-blind treatment period. Across all three treatment arms (placebo, 250 mg, 500 mg, each taken three times daily), the incidence of treatment-emergent adverse events were 80.8%, 100% and 84.0%, respectively; the incidence of serious AEs were 19.2%, 4.0% and 8.0%, respectively; and discontinuation due to AEs were 3.8%, 8.0% and 0%, respectively. AEs of depression or depressed mood were seen in two patients (7.7%) in the placebo arm and one (4.0%) in each of the telotristat ethyl treatment arms. Gastrointestinal AEs were seen in 57.7%, 64.0% and 36.0% of patients in the placebo, 250 mg and 500 mg treatment arms, respectively. Telotristat ethyl met the study's primary efficacy endpoint, the percent change from baseline in urinary 5-hydroxyindoleacetic acid (5-HIAA, the main metabolite of serotonin) at week 12, the final week of the double-blind treatment portion of the study (pless than0.001 for both telotristat ethyl arms compared to placebo). The placebo-adjusted change in 5-HIAA was -54.0% and -89.7% for the 250 mg and 500 mg treatment arms, respectively. In addition, despite the lower baseline bowel movement frequency than in TELESTAR, telotristat ethyl achieved statistically significant reductions in daily bowel movement frequency over the 12 weeks of the study (p=0.004 for the 250 mg treatment arm and pless than0.001 for the 500 mg treatment arm compared to placebo). Baseline mean daily bowel movement frequency was 2.2, 2.5 and 2.8 in the placebo, 250 mg and 500 mg arms. Patients in the 250 mg and 500 mg dose arms experienced noteworthy reductions in daily bowel movement frequency early in the study that tended to increase over time. The placebo-adjusted reduction in daily bowel movement frequency over the entire 12-week period was -0.45 and -0.54 for the 250 mg and 500 mg treatment arms, respectively. Notably, 40% of patients in each of the telotristat ethyl treatment arms achieved a greater than or equal to30% reduction in BM frequency for at least 50% of the days in the double-blind treatment period, while not a single patient in the placebo arm achieved that result (p=0.001 for both doses compared to placebo).

  • 30

    Nov

  • 28

    Feb

LXRX Lexicon
$18.07

0.17 (0.95%)

05/05/16
COWN
05/05/16
INITIATION
COWN
Market Perform
Lexicon coverage assumed with a Market Perform at Cowen
05/31/16
WEDB
05/31/16
NO CHANGE
Target $30
WEDB
Outperform
Lexicon price target raised to $30 from $28 at Wedbush
Wedbush analyst Liana Moussatos increased the firm's multiple on peak telotristat etiprate sales to 8x from 7x to reflect the reduced risk following the FDA's acceptance of the New Drug Application and raised the firm's price target accordingly to $30 from $28. Wedbush maintains its Outperform rating on Lexicon shares.
08/02/16
SBSH
08/02/16
INITIATION
Target $21
SBSH
Buy
Lexicon initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Lexicon Pharmaceuticals with a Buy rating and $21 price target. The analyst expects "timely approval and launch" of the company's lead drug telotristat etiprate, an add-on to standard of care to treat severe diarrhea in carcinoid syndrome patients. He believes this should provide near-term support for the stock.
09/12/16
SBSH
09/12/16
NO CHANGE
Target $25
SBSH
Buy
Lexicon price target raised to $25 from $21 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $25 saying sotagliflozin showed "strong efficacy" in its first Phase 3 trial in Type 1 diabetes mellitus. The analyst believes concerns over Sotagliflozin safety should be lifted on these data. He reiterates a Buy rating on Lexicon.

TODAY'S FREE FLY STORIES

02:45
02/24/17
02/24
02:45
02/24/17
02:45
General news
FX Action: The dollar has been in consolidation »

FX Action: The dollar has…

HL

Hecla Mining

$6.07

-0.29 (-4.56%)

21:32
02/23/17
02/23
21:32
02/23/17
21:32
Upgrade
Hecla Mining rating change  »

Hecla Mining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RIG

Transocean

$14.31

1.03 (7.76%)

21:31
02/23/17
02/23
21:31
02/23/17
21:31
Downgrade
Transocean rating change  »

Transocean downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CYOU

Changyou.com

$27.47

-0.56 (-2.00%)

21:30
02/23/17
02/23
21:30
02/23/17
21:30
Upgrade
Changyou.com rating change  »

Changyou.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOUR

Tuniu

$8.51

-0.2 (-2.30%)

21:30
02/23/17
02/23
21:30
02/23/17
21:30
Upgrade
Tuniu rating change  »

Tuniu upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFUN

Fang Holdings

$3.00

-0.02 (-0.66%)

21:30
02/23/17
02/23
21:30
02/23/17
21:30
Downgrade
Fang Holdings rating change  »

Fang Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YY

YY

$45.72

-1.16 (-2.47%)

21:29
02/23/17
02/23
21:29
02/23/17
21:29
Downgrade
YY rating change  »

YY downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$27.56

-0.22 (-0.79%)

21:26
02/23/17
02/23
21:26
02/23/17
21:26
Downgrade
Sunoco rating change  »

Sunoco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

QUNR

Qunar

$30.39

-0.22 (-0.72%)

20:25
02/23/17
02/23
20:25
02/23/17
20:25
Conference/Events
Qunar to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

COG

Cabot Oil & Gas

$22.53

-0.07 (-0.31%)

, FL

Foot Locker

$68.58

-2.44 (-3.44%)

20:25
02/23/17
02/23
20:25
02/23/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

COG

Cabot Oil & Gas

$22.53

-0.07 (-0.31%)

FL

Foot Locker

$68.58

-2.44 (-3.44%)

JCP

J.C. Penney

$6.86

-0.19 (-2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

IIPR

Innovative Industrial Properties

$18.05

0.05 (0.28%)

20:04
02/23/17
02/23
20:04
02/23/17
20:04
Hot Stocks
White House: Likely to see 'greater enforcement' of federal marijuana laws »

During a press briefing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

, SMCI

Super Micro Computer

$27.40

0.3 (1.11%)

19:55
02/23/17
02/23
19:55
02/23/17
19:55
Periodicals
Apple cut ties to Super Micro over security concerns, The Information says »

Apple (AAPL) terminated…

AAPL

Apple

$136.53

-0.58 (-0.42%)

SMCI

Super Micro Computer

$27.40

0.3 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 13

    Mar

HLF

Herbalife

$59.40

-1.34 (-2.21%)

19:45
02/23/17
02/23
19:45
02/23/17
19:45
Hot Stocks
Herbalife says board approves new $1.5B repurchase plan »

In its Q4 earnings report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AHT

Ashford Hospitality

$7.37

-0.13 (-1.73%)

19:17
02/23/17
02/23
19:17
02/23/17
19:17
Earnings
Ashford Trust reports Q4 AFFO 16c, may not compare to consensus (32c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

PG

Procter & Gamble

$91.13

-0.31 (-0.34%)

, EPC

Edgewell Personal Care

$76.27

-5.44 (-6.66%)

19:13
02/23/17
02/23
19:13
02/23/17
19:13
Hot Stocks
Procter & Gamble says cutting Gillette prices by double digits »

Speaking during the…

PG

Procter & Gamble

$91.13

-0.31 (-0.34%)

EPC

Edgewell Personal Care

$76.27

-5.44 (-6.66%)

UL

Unilever; also tag UN

$46.90

-0.03 (-0.06%)

UN

Unilever; also tag UL

$46.58

-0.17 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 19

    Mar

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:12
02/23/17
02/23
19:12
02/23/17
19:12
Hot Stocks
Nevsun Resources redeploys $120M to fund Timok »

Nevsun announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:11
02/23/17
02/23
19:11
02/23/17
19:11
Hot Stocks
Nevsun plans to drill over 130,000 meters during 2017 across 3 countries »

The company is planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:10
02/23/17
02/23
19:10
02/23/17
19:10
Hot Stocks
Nevsun sees Bisha processing 2.4M tonnes of primary one in FY17 »

Nevsun expects Bisha to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:10
02/23/17
02/23
19:10
02/23/17
19:10
Hot Stocks
Nevsun sees investing $45M at Timok Upper Zone Project in FY17 »

The company expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$2.94

-0.06 (-2.00%)

19:08
02/23/17
02/23
19:08
02/23/17
19:08
Earnings
Nevsun reports FY16 EPS 4c, consensus 7c »

Reports FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$76.88

-0.02 (-0.03%)

, S

Sprint

$8.96

-0.33 (-3.55%)

19:01
02/23/17
02/23
19:01
02/23/17
19:01
Hot Stocks
SoftBank, Sprint, TBCASoft partner in blockchain technology for telecoms »

SoftBank (SFTBF), Sprint…

SFTBF

SoftBank

$76.88

-0.02 (-0.03%)

S

Sprint

$8.96

-0.33 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

GOOG

Alphabet

$831.33

0.57 (0.07%)

, GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

18:59
02/23/17
02/23
18:59
02/23/17
18:59
Periodicals
Alphabet's Waymo sues Uber for allegedly stealing trade secrets, Bloomberg says »

Alphabet's Waymo…

GOOG

Alphabet

$831.33

0.57 (0.07%)

GOOGL

Alphabet Class A

$851.00

-0.36 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 06

    Mar

  • 19

    Mar

ALB

Albemarle

$92.41

-0.03 (-0.03%)

18:57
02/23/17
02/23
18:57
02/23/17
18:57
Hot Stocks
Albemarle raises quarterly dividend 5% to 32c from 30.5c per share »

The dividend, which has a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

UTX

United Technologies

$112.09

-0.57 (-0.51%)

18:32
02/23/17
02/23
18:32
02/23/17
18:32
Hot Stocks
Carrier expands air conditioner, heat pump recall »

United Technologies'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

, BUD

AB InBev

$108.76

-0.4 (-0.37%)

18:17
02/23/17
02/23
18:17
02/23/17
18:17
Hot Stocks
Craft Brew reschedules Q4 report to allow additional time for audit »

Craft Brew Alliance…

BREW

Craft Brew

$15.60

-0.25 (-1.58%)

BUD

AB InBev

$108.76

-0.4 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.